Plain-English translation of NCT04781140 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 4 โ The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether a medication called SPN-812 (viloxazine extended-release) can help young children ages 4 to 5 who have been diagnosed with ADHD and are struggling to pay attention or control their behavior. Half of the children will receive the medication, and half will receive a placebo (a pill with no active medicine) so researchers can see if the real medication works better. The study will measure whether the medication helps reduce ADHD symptoms and is safe for this young age group.
ADHD in very young children is challenging to treat, and there are limited medication options available specifically tested and approved for preschoolers. This research aims to determine if this medication is an effective and safe choice for this younger population.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If your child is selected, you will first go through a screening period of up to 4 weeks where the research team will confirm the ADHD diagnosis and collect baseline information. Then your child will take either the study medication or a placebo once daily for 6 weeks, while the research team monitors symptoms and watches for any side effects through clinic visits. The entire study lasts about 10 weeks from start to finish. You and your child's teachers or daycare providers will be asked to report on how your child is doing during this time.
AI-generated summary from trial data ยท Sep 18, 2026 ยท Not medical advice
United States